Ocular Therapeutix

OCUL

Market cap $2.36B

The biotechnology sector's strong fundamentals and robust innovation could continue to drive outperformance this year, according to Baird analysts. The firm noted that while macroeconomic risks such as rising interest rates remain, the biotechnology sector's underlying drivers are supportive.

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).

BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago.

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD) has achieved its randomization target of 555 subjects.

The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

After losing some value lately, a hammer chart pattern has been formed for Ocular Therapeutix (OCUL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.